^
    Back
    Association details:
    Biomarker:SLC12A2-ROS1 fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    SAGE Open Med Case Rep
    Title:

    Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma

    Published date:
    05/21/2022
    Excerpt:
    ...a case of a 26-year-old never-smoker patient from southern Africa with metastatic lung adenocarcinoma driven by SLC12A2-ROS1 fusion, who had a pronounced and durable response to crizotinib.
    DOI:
    https://doi.org/10.1177/2050313X221100407
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    The Oncologist
    Title:

    Novel SLC12A2-ROS1 fusion in non-small-cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay

    Published date:
    03/08/2021
    Excerpt:
    We detected the SLC12A2‐ROS1 fusion by FISH this is the first description of a SLC12A2‐ROS1 fusion....Considering the patient's clinical features and tumor response observed after crizotinib therapy, we can confirm that this new rearrangement has relevant clinical impact for patients with NSCLC.
    DOI:
    10.1002/onco.13745